Investor Contact

Media & Investor Relations:
Troy Wichterman 
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc. 
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.

Press Releases

BioLife Solutions to Present at Upcoming Investor Conferences
PR Newswire
BOTHELL, Wash.

BOTHELL, Wash., Sept. 28, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced Mike Rice, President and Chief Executive Officer, will be presenting at several upcoming investor conferences as follows:

Ladenburg Thalmann 2015 Healthcare Conference
When: September 29, 2015 at 9:00am
Where: Sofitel Hotel, New York

2015 Stem Cell Meeting on the Mesa – Partnering Forum
When: October 7, 2015 at 4:00pm
Where: Estancia La Jolla Hotel & Spa, La Jolla

2015 Aegis Growth Conference
When: October 9, 2015 at 8:30am
Where: The Encore at Wynn Las Vegas

Dawson James Securities 2015 Growth Stock Conference
When: October 15, 2015 at 1:45pm
Where: Wyndham Grand Hotel, Jupiter Florida

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and smart shipping containers connected to a cloud hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

Media & Investor Relations



Daphne Taylor



Senior Vice President, Chief Financial Officer



(425) 402-1400



dtaylor@biolifesolutions.com






 

SOURCE BioLife Solutions, Inc.